Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis

Bei Li, Chuan Zhang, Yu-Tao Zhan, Bei Li, Chuan Zhang, Yu-Tao Zhan

Abstract

Cirrhosis is the common end stage of a number of chronic liver conditions and a significant cause of morbidity and mortality. With the growing epidemic of obesity and metabolic syndrome, nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease worldwide and will become one of the leading causes of cirrhosis. Increased awareness and understanding of NAFLD cirrhosis are essential. To date, there has been no published systematic review on NAFLD cirrhosis. Thus, this article reviews recent studies on the epidemiology, risk factors, clinical presentation, diagnosis, management, and prognosis of NAFLD cirrhosis.

Figures

Figure 1
Figure 1
Proposal of diagnostic algorithm for classification of patients affected by NAFLD. NAFLD: nonalcoholic fatty liver disease; NFS: NAFLD fibrosis score; TE: transient elastography; LSE: liver stiffness measurement; kPa: kilopascal.

References

    1. de la Garza R. G., Morales-Garza L. A., Martin-Estal I., Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and cirrhosis establishment. Journal of Clinical Medicine Research. 2017;9(4):G233–G247. doi: 10.14740/jocmr2761w.
    1. Stasi C., Silvestri C., Voller F., Cipriani F. Epidemiology of liver cirrhosis. Journal of Clinical and Experimental Hepatology. 2015;5(3):p. 272. doi: 10.1016/j.jceh.2015.06.002.
    1. Abbas N., Makker J., Abbas H., Balar B. Perioperative care of patients with liver cirrhosis: a review. Health Services Insights. 2017:G1–G12.
    1. Mokdad A. A., Lopez A. D., Shahraz S. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Medicine. 2014;12, article 145 doi: 10.1186/s12916-014-0145-y.
    1. Safaei A., Oskouie A. A., Mohebbi S. R., et al. Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases. Gastroenterol Hepatol Bed Bench. 2016;9(3):G158–G173.
    1. Kadayifci A., Tan V., Ursell P. C., Merriman R. B., Bass N. M. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: A comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. Journal of Hepatology. 2008;49(4):595–599. doi: 10.1016/j.jhep.2008.05.024.
    1. van den Berg E. H., Douwes R. M., de Meijer V. E., Schreuder T. C., Blokzijl H. Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity. Digestive and Liver Disease. 2018;50(1):G68–G75. doi: 10.1016/j.dld.2017.08.022.
    1. Wree A., Broderick L., Canbay A., Hoffman H. M., Feldstein A. E. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nature Reviews Gastroenterology & Hepatology. 2013;10(11):G627–G636. doi: 10.1038/nrgastro.2013.149.
    1. Younossi Z. M., Koenig A. B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):G73–G84.
    1. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology. 2010;51(2):G373–G375. doi: 10.1002/hep.23521.
    1. Kabbany M. N., Selvakumar P. K. C., Watt K., et al. Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of national health and nutrition examination survey data. American Journal of Gastroenterology. 2017;112(4):G581–G587. doi: 10.1038/ajg.2017.5.
    1. Fung J., Lee C.-K., Chan M., Seto W.-K., Lai C.-L., Yuen M.-F. High prevalence of non-alcoholic fatty liver disease in the Chinese—results from the Hong Kong liver health census. Liver International. 2015;35(2):G542–G549. doi: 10.1111/liv.12619.
    1. Kwok R., Choi K. C., Wong G. L.-H., et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65:G1359–G1368.
    1. Lonardo A., Nascimbeni F., Mantovani A., Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? Journal of Hepatology. 2018;68(2):G335–G352. doi: 10.1016/j.jhep.2017.09.021.
    1. Xiong J., Wang J., Huang J., Sun W., Wang J., Chen D. Non-alcoholic steatohepatitis-related liver cirrhosis is increasing in China: a ten-year retrospective study. Clinics. 2015;70(8):G563–G568. doi: 10.6061/clinics/2015(08)06.
    1. Michitaka K., Nishiguchi S., Aoyagi Y., Hiasa Y., Tokumoto Y., Onji M. Etiology of liver cirrhosis in Japan: a nationwide survey. Journal of Gastroenterology. 2010;45(1):G86–G94. doi: 10.1007/s00535-009-0128-5.
    1. Karageorgos S. A., Stratakou S., Koulentaki M., et al. Long-term change in incidence and risk factors of cirrhosis and hepatocellular carcinoma in crete, Greece: a 25-year study. Annals of Gastroenterology. 2017;30(3):G357–G363.
    1. Hsiang J. C., Bai W. W., Raos Z., et al. Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand. Internal Medicine Journal. 2015;45(2):G160–G169. doi: 10.1111/imj.12624.
    1. Holmer M., Melum E., Isoniemi H., et al. Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. Liver International. 2018:G1–G9.
    1. Doycheva I., Issa D., Watt K. D., Lopez R., Rifai G., Alkhouri N. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in young adults in the United States. Journal of Clinical Gastroenterology. 2018;52(4):G339–G346. doi: 10.1097/MCG.0000000000000925.
    1. Parikh N. D., Marrero W. J., Wang J., et al. Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States. Hepatology. 2017 doi: 10.1002/hep.29473.
    1. Siddiqui M. S., Fuchs M., Idowu M. O., et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clinical Gastroenterology and Hepatology. 2015;13(5):G1000–G1008.e3. doi: 10.1016/j.cgh.2014.10.008.
    1. Marengo A., Jouness R. I. K., Bugianesi E. Progression and natural history of nonalcoholic fatty liver disease in adults. Clinics in Liver Disease. 2016;20(2):G313–G324. doi: 10.1016/j.cld.2015.10.010.
    1. Singh S., Allen A. M., Wang Z., Prokop L. J., Murad M. H., Loomba R. Sa1052 fibrosis progression in nonalcoholic fatty liver versus nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Gastroenterology. 2014;146(5):G947–G948. doi: 10.1016/S0016-5085(14)63443-0.
    1. Valenti L., Bugianesi E., Pajvani U., Targher G. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? Liver International. 2016;36(11):G1563–G1579. doi: 10.1111/liv.13185.
    1. Porepa L., Ray J. G., Sanchez-Romeu P., Booth G. L. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. Canadian Medical Association Journal. 2010;182(11):E526–E531. doi: 10.1503/cmaj.092144.
    1. Nderitu P., Bosco C., Garmo H., et al. The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: a study in the Swedish AMORIS cohort. International Journal of Cancer. 2017;141(6):G1148–G1160. doi: 10.1002/ijc.30818.
    1. Anstee Q. M., Seth D., Day C. P. Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease. Gastroenterology. 2016;150(8):G1728–G1744. doi: 10.1053/j.gastro.2016.01.037.
    1. Valenti L., Al-Serri A., Daly A. K., et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin i148m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51(4):G1209–G1217. doi: 10.1002/hep.23622.
    1. Liu Y. L., Reeves H. L., Burt A. D., et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nature Communications. 2014;5:p. G4309.
    1. Frith J., Day C. P., Henderson E., Burt A. D., Newton J. L. Non-alcoholic fatty liver disease in older people. Gerontology. 2009;55(6):G607–G613. doi: 10.1159/000235677.
    1. Noureddin M., Yates K. P., Vaughn I. A., et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. 2013;58(5):G1644–G1654. doi: 10.1002/hep.26465.
    1. Vernon G., Baranova A., Younossi Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology & Therapeutics. 2011;34(3):G274–G285. doi: 10.1111/j.1365-2036.2011.04724.x.
    1. Ballestri S., Nascimbeni F., Baldelli E., Marrazzo A., Romagnoli D., Lonardo A. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Advances in Therapy. 2017;36:G1291–G1326.
    1. Rich N. E., Oji S., Mufti A. R., et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis. Clinical Gastroenterology and Hepatology. 2018;16(2):198–210.e2. doi: 10.1016/j.cgh.2017.09.041.
    1. Bhadoria A. S., Kedarisetty C. K., Bihari C., et al. Impact of family history of metabolic traits on severity of non-alcoholic steatohepatitis related cirrhosis: a cross-sectional study. Liver International. 2017;37(9):G1397–G1404. doi: 10.1111/liv.13396.
    1. Hui J. M., Kench J. G., Chitturi S., et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003;38(2):G420–G427. doi: 10.1053/jhep.2003.50320.
    1. Yatsuji S., Hashimoto E., Tobari M., Taniai M., Tokushige K., Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. Journal of Gastroenterology and Hepatology. 2009;24(2):G248–G254. doi: 10.1111/j.1440-1746.2008.05640.x.
    1. Bhala N., Angulo P., van der Poorten D., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54(4):G1208–G1216. doi: 10.1002/hep.24491.
    1. Dyson J. K., Anstee Q. M., McPherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol. 2014;5:G277–G286. doi: 10.1136/flgastro-2013-100404.
    1. Caldwell S., Argo C. The natural history of non-alcoholic fatty liver disease. Digestive Diseases. 2010;28(1):G162–G168. doi: 10.1159/000282081.
    1. Brown G. T., Kleiner D. E. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism—Clinical and Experimental. 2016;65(8):G1080–G1086. doi: 10.1016/j.metabol.2015.11.008.
    1. Shen F., Zheng R. D., Mi Y. Q., et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World Journal of Gastroenterology. 2014;20(16):G4702–G4711. doi: 10.3748/wjg.v20.i16.4702.
    1. Laurent C. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: non-invasive tests are enough. Liver International. 2018;38:G67–G70. doi: 10.1111/liv.13658.
    1. Koehler E. M., Plompen E. P. C., Schouten J. N. L., et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology. 2016;63(1):G138–G147. doi: 10.1002/hep.27981.
    1. Hashemi S.-A., Alavian S.-M., Gholami-Fesharaki M. Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Caspian Journal of Internal Medicine. 2016;7(4):G242–G252.
    1. Dyson J. K., Anstee Q. M., McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterology. 2014;5(3):G211–G218. doi: 10.1136/flgastro-2013-100403.
    1. Festi D., Schiumerini R., Marasco G., Scaioli E., Pasqui F., Colecchia A. Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. Expert Review of Gastroenterology & Hepatology. 2015;9(8):G1039–1053. doi: 10.1586/17474124.2015.1049155.
    1. De Lédinghen V., Wong V. W.-S., Vergniol J., et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan. Journal of Hepatology. 2012;56(4):G833–G839. doi: 10.1016/j.jhep.2011.10.017.
    1. Imajo K., Kessoku T., Honda Y., et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology. 2016;150(3):626–637.e7. doi: 10.1053/j.gastro.2015.11.048.
    1. Stål P. Liver fibrosis in non-alcoholic fatty liver disease—diagnostic challenge with prognostic significance. World Journal of Gastroenterology. 2015;21(39):G11077–G11087. doi: 10.3748/wjg.v21.i39.11077.
    1. Chalasani N., Younossi Z., Lavine J. E., et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology. 2018;67(1):G328–G357.
    1. Festi D., Schiumerini R., Marasco G., Scaioli E., Pasqui F., Colecchia A. Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. Expert Review of Gastroenterology & Hepatology. 2015;9(8):G1039–G1053. doi: 10.1586/17474124.2015.1049155.
    1. Newsome P. N., Allison M. E., Andrews P. A., et al. Guidelines for liver transplantation for patients with alcoholic steatohepatitis. Gut. 2012;61(4):G484–G500.
    1. Wattacheril J., Issa D., Sanyal A. Nonalcoholic Steatohepatitis (NASH) and hepatic fibrosis: emerging therapies. Annual Review of Pharmacology and Toxicology. 2018;58(1):G649–G662. doi: 10.1146/annurev-pharmtox-010617-052545.
    1. Garcia-Tsao G., Abraldes J. G., Berzigotti A., Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65(1):G310–G335. doi: 10.1002/hep.28906.
    1. Than N. N., Ghazanfar A., Hodson J., et al. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM. 2017;110(2):G73–G81.
    1. Shetty K., Chen J., Shin J., Jogunoori W., Mishra L. Pathogenesis of hepatocellular carcinoma development in non-alcoholic fatty liver disease. Current Hepatology Reports. 2015;14(2):G119–G127. doi: 10.1007/s11901-015-0260-z.
    1. Baffy G., Brunt E. M., Caldwell S. H. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. Journal of Hepatology. 2012;56(6):1384–1391. doi: 10.1016/j.jhep.2011.10.027.
    1. Degasperi E., Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. The Lancet Gastroenterology & Hepatology. 2016;1(2):G156–G164. doi: 10.1016/S2468-1253(16)30018-8.
    1. Heimbach J. K., Kulik L. M., Finn R. S., et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi: 10.1002/hep.29086.
    1. Wainwright P., Scorletti E., Byrne C. D. Type 2 diabetes and hepatocellular carcinoma: risk factors and pathogenesis. Current Diabetes Reports. 2017;17(4, article 20) doi: 10.1007/s11892-017-0851-x.
    1. El-Serag H. B., Johnson M. L., Hachem C., Morgana R. O. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009;136(5):G1601–G1608. doi: 10.1053/j.gastro.2009.01.053.
    1. Khan R. S., Newsome P. N. Non-alcoholic fatty liver disease and liver transplantation. Metabolism. 2016;65(8):G1208–G1223. doi: 10.1016/j.metabol.2016.02.013.
    1. Zezos P., Renner E. L. Liver transplantation and non-alcoholic fatty liver disease. World Journal of Gastroenterology. 2014;20(42):G15532–G15538. doi: 10.3748/wjg.v20.i42.15532.
    1. Sanyal A. J., Banas C., Sargeant C., et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43(4):G682–G689. doi: 10.1002/hep.21103.
    1. Ratziu V., Bonyhay L., Di Martino V., et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35(6):G1485–G1493. doi: 10.1053/jhep.2002.33324.
    1. Rinaldi L., Nascimbeni F., Giordano M., et al. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. World Journal of Gastroenterology. 2017;23(8):1458–1468. doi: 10.3748/wjg.v23.i8.1458.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever